Loading…
AgomAb Therapeutics NV is projected to decline to $12.54 by 2027, a -3% move from its current price of $12.87. AGMB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $12.32 | $12.87 | $13.46 | +0.03% |
| Aug 3 | $12.09 | $12.88 | $13.71 | +0.06% |
| Aug 4 | $11.93 | $12.88 | $13.91 | +0.09% |
| Aug 5 | $11.79 | $12.89 | $14.08 | +0.12% |
| Aug 6 | $11.67 | $12.89 | $14.23 | +0.15% |
| Aug 7 | $11.57 | $12.89 | $14.37 | +0.18% |
| Aug 8 | $11.47 | $12.90 | $14.50 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.47 | $12.90 | $14.50 | +0.21% |
| Week 2 | $10.95 | $12.92 | $15.26 | +0.42% |
| Week 3 | $10.57 | $12.95 | $15.87 | +0.63% |
| Week 4 | $10.26 | $12.98 | $16.41 | +0.84% |
| Week 5 | $10.00 | $13.01 | $16.91 | +1.05% |
| Week 6 | $9.78 | $13.03 | $17.37 | +1.27% |
| Week 7 | $9.57 | $13.06 | $17.82 | +1.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AgomAb Therapeutics NV (AGMB) is a clinical-stage biopharmaceutical company operating in the healthcare sector. It focuses on developing novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
AGomAb Therapeutics NV, ticker AGMB, trades in the healthcare sector with a current price of $12.32 and a market capitalization of $606.74M. It ranks 2842 by market capitalization among listed assets. The latest available forecast shows a path of gradual price development with meaningful upside over the longer term.
A major floor 45.2% below — a decisive break under it would weaken the trend.
The nearest floor, 14.7% below — buyers have tended to step in here.
The nearest ceiling, 38.5% above — a clean break opens room to run.
A major ceiling 61.1% above — clearing it would confirm fresh momentum.
Key AGMB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AGMB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.62 | Buy | $12.65 | Buy |
| MA 10 | $12.38 | Buy | $12.54 | Buy |
| MA 20 | $12.54 | Buy | $12.46 | Buy |
| MA 50 | $11.93 | Buy | $12.19 | Buy |
| MA 100 | $11.75 | Buy | $12.32 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.98 | Neutral |
| Stoch RSI (14) | 95.56 | Sell |
| CCI (20) | 54.77 | Neutral |
| Williams %R (14) | -7.30 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 1.90 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 92.70 | Sell |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | 0.25 | Buy |
| Ultimate (7,14,28) | 66.90 | Neutral |
| Momentum (10) | 0.83 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 12.74 | Buy |
| ADX (14) | 7.81 | Neutral |
| ATR (14) | 0.47 | Info |
The 30-day technical picture is NEUTRAL. The RSI(14) is 50, and the 50-day simple moving average stands at $11.74. The price faces resistance at $17.82 and has support at $9.61. The 30-day price range spans from $8.56 to $17.72, and the asset exhibits an annualized volatility of 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.61 | $12.87 | $17.46 | 0% | Neutral | |
| $8.70 | $12.54 | $19.62 | -3% | Neutral | |
| $9.38 | $14.67 | $24.76 | +14% | Neutral | |
| $9.56 | $16.05 | $28.68 | +25% | Bullish | |
| $10.49 | $18.79 | $35.19 | +46% | Bullish | |
| $13.42 | $25.59 | $49.88 | +99% | Bullish | |
| $13.26 | $26.84 | $54.20 | +109% | Bullish | |
| $12.66 | $27.18 | $56.64 | +111% | Bullish | |
| $13.16 | $29.24 | $62.69 | +127% | Bullish | |
| $11.75 | $26.11 | $57.47 | +103% | Bullish | |
| $23.34 | $51.87 | $119.31 | +303% | Bullish | |
| $36.78 | $81.74 | $187.99 | +535% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $9.61 | $12.87 | $16.14 | +0.00% |
| September 2026 | $10.28 | $12.70 | $16.49 | -1.31% |
| October 2026 | $10.52 | $13.23 | $17.59 | +4.13% |
| November 2026 | $10.44 | $13.31 | $18.04 | +0.60% |
| December 2026 | $9.80 | $12.66 | $17.46 | -4.87% |
Click any year to see its month-by-month AGMB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AGMB could reach as high as $17.46, with a base case around $12.87 and support toward $9.61 — roughly 0% from $12.87. Price action looks broadly range-bound.
Expect AGMB to range from $8.70 to $19.62 through 2027. The $12.54 average target implies a -3% move from current prices. That is -3% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The AGMB price prediction for 2028 points to an average of $14.67 (low $9.38, high $24.76) — a potential gain of +14% on today's $12.87. Price action looks broadly range-bound.
In 2029, AGMB is projected to trade between $9.56 and $28.68, averaging $16.05 — a potential gain of +25% from today's $12.87. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
AgomAb Therapeutics NV's 2030 outlook centres on $18.79, within a $10.49 to $35.19 range. That is up +17% on the projected 2029 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2031, AGMB could reach as high as $49.88, with a base case around $25.59 and support toward $13.42 — roughly +99% from $12.87. Buyers look set to stay in control over this stretch.
Expect AGMB to range from $13.26 to $54.20 through 2032. The $26.84 average target implies a +109% move from current prices. That is up +5% on the projected 2031 average. Momentum favours further upside here.
The AGMB price prediction for 2033 points to an average of $27.18 (low $12.66, high $56.64) — a potential gain of +111% on today's $12.87. Buyers look set to stay in control over this stretch.
In 2034, AGMB is projected to trade between $13.16 and $62.69, averaging $29.24 — a potential gain of +127% from today's $12.87. That is up +8% on the projected 2033 average. Momentum favours further upside here.
AgomAb Therapeutics NV's 2035 outlook centres on $26.11, within a $11.75 to $57.47 range. That is -11% versus the projected 2034 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, AGMB could reach as high as $119.31, with a base case around $51.87 and support toward $23.34 — roughly +303% from $12.87. Momentum favours further upside here.
Expect AGMB to range from $36.78 to $187.99 through 2050. The $81.74 average target implies a +535% move from current prices. That is up +58% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AGMB today (≈ 77.700078 AGMB) could be worth
$6,350.94
+$5,350.94 (+535%) by 2050 · US Dollar
Based on the average projected AGMB price of $81.74 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AGMBwould be worth at today's price.
$1,000 invested in AGMB on Feb 6, 2026 (≈ 68.259387 AGMB) would be worth
$878.5
-$121.5 (-12.2%) today · 0.88× · US Dollar
Based on a AGMB entry price of $14.65 vs. today's $12.87.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.51 | $1,028.78 | +2.9% |
| 1 month ago | $11.87 | $1,084.25 | +8.4% |
| 3 months ago | $11.19 | $1,150.13 | +15.0% |
| All time ago | $14.65 | $878.5 | -12.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AGMB forecast.
Our base-case forecast reaches $26.00 around 2032.
Implied market cap at $26.00: $1.28B
The multi-year forecast shows a steady start with 2026’s average price at $12.32 and a 2026 min/max of $9.61/$16.63, respectively, with a 0% ROI and NEUTRAL sentiment. The trajectory picks up in subsequent years, with 2030 averaging $14.71 and a max of $29.75 (ROI 19.4; sentiment NEUTRAL). From 2031 onward, the outlook turns more bullish, as indicated by higher averages and rising ROIs (2031 AVG $20.23; ROI 64.2; 2032 AVG $21.35; ROI 73.3; 2033 AVG $21.11; ROI 71.4; 2034 AVG $21.30; ROI 72.9; 2035 AVG $18.39; ROI 49.3).
The forecast further envisions substantial upside by 2040 (AVG $36.42; ROI 195.6; max $83.77) and by 2050 (AVG $50.43; ROI 309.4; max $116.00). These estimates reflect a long-run bullish bias, though they are not guarantees and carry inherent uncertainty and risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $14.71 with a low of $7.25 and a high of $29.75, and a forecasted ROI of 19.4, with neutral sentiment.
The 2050 forecast projects an average price of $50.43, with a high of $116.00 and a forecasted ROI of 309.4, indicating the possibility of reaching around $50 on average by 2050 within a bullish long-term outlook.
The current price is $12.32 and the market capitalization is $606.74M.
The 30-day picture shows NEUTRAL sentiment with RSI(14) at 50, a 50-day SMA of $11.74, support at $9.61, and resistance at $17.82. The 30-day price range runs from $8.56 to $17.72.
The 2050 forecast max is $116.00, with an average of $50.43 and a max of $116.00, indicating that a peak around or above $100 is within the model’s high-end projection but not guaranteed.
AgomAb Therapeutics NV Community Discussion
0Share your AgomAb Therapeutics NV price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.